Clinical trials: Liver Dysfunction
Acute Hepatitis
ADRENAL FUNCTION IN PATIENTS WITH ACUTE HEPATITIS
A high frequency of adrenal dysfunction (AD) has been reported in severe acute hepatitis (SAH) using the dosage of serum total cortisol (STC).
- Trial name
- CORT-HEPAT (NCT02859584)
- Testing
- Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hepatic Insufficiency, Healthy
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female…
- Trial name
- NCT05440344
- Testing
- Imlunestrant
- Where
- 3 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Hepatic Dysfunction, Moderate Hepatic Dysfunction
Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction
This is a Phase I, open-label, single-dose study designed to assess the effects of hepatic dysfunction on the PK of orally administered Fx-1006A 20 mg soft gelatin capsules. An adaptive 2-stage study design will be implemented.
- Trial name
- NCT01358565
- Testing
- Fx-1006A
- Where
- South Africa
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease )
A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth…
- Conditions
- NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease ), NAFLD Cirrhosis
- Trial name
- COMET cohort (NCT07241195)
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Liver Dysfunction, Healthy Volunteers
An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage
The purpose of this study is to investigate BMS-986165 in participants with different levels of liver function.
- Trial name
- NCT03890809
- Testing
- BMS-986165
- Where
- 4 sites in Czechia, Hungary and 1 more
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Fatty Liver Disease
Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting
This study consists of 2 parts: Part 1: a cross-sectional study, looking at the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) among nurses in Hospital Canselor Tuanku Muhriz (HCTM).
- Trial name
- NCT05880316
- Testing
- Intermittent Fasting
- Where
- Malaysia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre
Liver Dysfunction, Liver Insufficiency
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.
- Conditions
- Liver Dysfunction, Liver Insufficiency, Hepatic Failure, Myocardial Failure
- Trial name
- NCT03515980
- Testing
- BMS-986231
- Where
- 4 sites in Hungary, Poland
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy, Hepatic Insufficiency
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants.
- Trial name
- NCT06190691
- Testing
- Pirtobrutinib
- Where
- 8 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Fatty Liver, Nonalcoholic
Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease
Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
- Trial name
- NCT06491342
- Testing
- Probiotic
- Where
- 2 sites in Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Hepatitis C, Cognitive Impairment
P300 in Early Cognitive Impairment in Hepatitis C Virus
Approximately 50% of patients with hepatitis C have complaints of fatigue and cognitive deficits even before the development of significant hepatic impairment.
- Trial name
- NCT04389268
- Testing
- Visual Event-Related Potentials
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mansoura University Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
The goal of this observational, cross-sectional, case-control clinical study is to investigate the metabolic adaptations underlying the progression of nonalcoholic fatty liver disease (NAFLD), and to test the hypothesis that…
- Trial name
- ECHO (NCT06942312)
- Testing
- Ketoisocaproic acid breath test, Ammonium Chloride, Bicarbonate de sodium
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Hepatic Insufficiency
Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency
To evaluate and compare the safety and efficacy of FCN-437c in subjects with mild and moderate liver impairment and healthy subjects, and to provide a basis for clinical medication in patients with liver impairment.
- Trial name
- NCT06620731
- Testing
- FCN-437c capsule
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ahon Pharmaceutical Co., Ltd.
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver disorders ranging from simple steatosis-a relatively benign and non-progressive condition-to metabolic dysfunction-associated…
- Trial name
- MASLD-GUT (NCT07313007)
- Testing
- stool sampling, dietary assessment, and collection of blood and urine samples
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Steatosis of Liver
Assessment the Diagnostic Value of Pro-Neurotensin as a Serum Biomarker in MASLD
To assess the diagnostic significance of serum pro-NT in MASLD and ability to differentiate between early and advanced steatosis.
- Trial name
- NCT06453239
- Testing
- Pro-Neurotensin level as a Serum Biomarker
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Liver Dysfunction
Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
The objective of the study is to compare the pharmacokinetics profiles and safety of Evogliptin in patients wit hepatic dysfunction versus healthy volunteers after single oral dose of Evogliptin
- Trial name
- NCT02754219
- Testing
- Evogliptin
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Liver Cirrhosis, Liver Failure
Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"
The purpose of this study is to evaluate the effects on plasma exchange with 5% albumin on albumin functional capacity, cardiocirculatory, renal and cerebral function in cirrhotic patients with "acute-on-chronic liver failure".
- Trial name
- NCT01201720
- Testing
- Plasma exchange with albumin
- Where
- Spain
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Instituto Grifols, S.A.
Hepatic Impairment, Healthy
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy…
- Trial name
- NCT06908954
- Testing
- Palovarotene
- Where
- 4 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Ipsen
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Study on Risk Factors and Prognosis of MASLD
This longitudinal cohort study will enroll individuals with MASLD (and/or those at risk) and follow them over time to identify clinical and metabolic risk factors for disease progression and to evaluate predictors of long-term…
- Trial name
- NCT07433205
- Where
- China
- Volunteers
- 922 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Liver Cirrhoses, Peripheral Neuropathy
Electrophysiological Evaluation of Motor Dysfunction in Liver Cirrhotic Patients
cross sectional observational study, aimed to assess the electrophysiological function of the motor units in liver cirrhotic patients.
- Trial name
- NCT04340999
- Testing
- Nerve conduction studies and Quantitative EMG ( MUNE and IPA)
- Where
- Egypt
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital
Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease
Positive Association of US-FLI With the Severity of CAD
As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD).
- Conditions
- Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease, SYNTAX Score, Ultrasonography
- Trial name
- NCT06541132
- Testing
- Observational study without human intervention
- Where
- China
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Chongqing Medical University